Cystic fibrosis (CF) is an inherited condition that can affect breathing, digestion and other body systems. A positive newborn screen, a CFTR carrier result and a confirmed CF diagnosis are different findings. This guide explains how they fit together and helps families, students and health professionals prepare better questions. [1]
In this guide: What does cystic fibrosis affect? · How is CF diagnosed? Follow the evidence in order · Carrier, uncertain result or CF: what is the difference? · What changes after a diagnosis? · Questions to take to an appointment · Common questions
What does cystic fibrosis affect?
CF involves abnormal salt and water handling at epithelial surfaces—the cells lining organs and ducts. Thick secretions can contribute to lung infections and digestive problems. Some people have pancreatic insufficiency, meaning too few digestive enzymes reach the intestine; others retain pancreatic function. Features and severity vary. A person need not have every familiar symptom to need assessment. [1]
The gene involved is CFTR. Its protein helps transport chloride across cell membranes. A gene name alone does not describe someone’s lung function, nutritional needs or future. The companion CFTR gene guide focuses on the molecular result; this article focuses on the diagnostic and family questions. [2]
How is CF diagnosed? Follow the evidence in order
- Identify the starting point. Is this follow-up after newborn screening, an investigation of symptoms, or testing because of a relative’s result? Screening identifies a need for further assessment; it does not complete that assessment.
- Obtain the actual reports. Record the newborn-screen result, sweat chloride value and units, and the complete genetic report. A message saying “positive” cannot substitute for these details.
- Arrange specialist interpretation. Sweat testing measures chloride in collected sweat. Test quality, clinical findings and genetic evidence belong in the same assessment.
- Clarify unresolved findings. An inconclusive result may require repeat testing, more extensive genetic analysis or specialist functional studies. Ask what remains uncertain and who is responsible for follow-up.
NHLBI describes diagnosis as a combination of symptoms, genetic testing and sweat chloride testing. Keep the referral and follow-up process active rather than trying to settle the diagnosis with an internet search. [3]
In the appropriate clinical setting, the Cystic Fibrosis Foundation diagnostic guidance uses sweat chloride of 60 mmol/L or above as evidence supporting CF; 30–59 mmol/L is an intermediate range requiring further evaluation. Below 30 makes CF less likely, but does not exclude every relevant clinical situation. These are interpretation aids for a properly performed test, not a home diagnostic score. [4]
Carrier, uncertain result or CF: what is the difference?
CF is usually inherited in an autosomal recessive pattern. If both parents carry a CF-causing variant, each pregnancy has a 25% chance of inheriting both variants, a 50% chance of inheriting one and a 25% chance of inheriting neither. These probabilities restart with each pregnancy; four children are not guaranteed to occupy four different outcome categories. [5]
One identified variant often indicates carrier status, but the reason for testing and the test’s coverage still matter. Conversely, simply counting two listed variants is insufficient: their clinical significance and whether they affect opposite gene copies matter. The absence of two detected CF-causing variants does not, by itself, exclude CF. [4]
Some screen-positive infants have an inconclusive designation called CRMS/CFSPID. Some individuals have a CFTR-related disorder without meeting CF diagnostic criteria. These labels describe different clinical circumstances and need an appropriate follow-up plan; they are not interchangeable shorthand for confirmed CF. [4]
What changes after a diagnosis?
Care is individualized and may address airway clearance, infections, nutrition, digestion and other complications. CFTR modulators act on particular protein defects and may be appropriate for eligible patients. Eligibility and monitoring depend on the specific medicine, genetic findings, age and clinical circumstances. Do not infer eligibility from this guide or change treatment without the CF team. [6]
For researchers, keep three outcomes separate: a laboratory measure of CFTR function, a clinical measurement such as lung function, and a patient-important outcome such as symptoms or hospital use. A study should specify which it measured and for how long. Use our guide to reading gene therapy trial results when assessing emerging interventions.
Questions to take to an appointment
- What evidence supports the current diagnosis or provisional label?
- Was the sweat sample adequate, and is a repeat required?
- What exactly did the genetic test cover? Are the findings on opposite gene copies?
- Which symptoms, nutritional measures and organ systems need follow-up?
- Would relatives benefit from counseling or targeted testing?
- Who will explain a changed interpretation or updated treatment option?
Use the variant research assistant to organize a non-identifying CFTR query and download a checklist; it does not diagnose CF. Use the care finder to locate genetics services, the research tools for original literature, or the disease finder for related topics.
Common questions
Can CF be diagnosed in adulthood?
Yes. CF is not exclusively a childhood diagnosis. The clinical picture and previous testing must be reviewed rather than assuming that age rules it out. [5]
Can a negative genetic panel end the investigation?
Not always. The conclusion depends on what the test could detect and the other evidence. Read what a genetic test can miss before treating “not detected” as “impossible.”
This educational guide and its original diagrams do not provide an individual diagnosis or treatment plan. The article’s current specialist-review status is shown above.